Sai Life Sciences completes Phase II of production block 11 at Bidar
With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL
With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL
New manufacturing facility in Mebane to produce at least 40 million laboratory pipette tips per week
Investment supports Company’s plans to manufacture the vast majority of advanced medicines in the U.S. to meet the needs of patients in the U.S.
This project shall be implemented through incorporation of a new joint venture company in Zambia
This strategic investment strengthens Cohance's integrated oligonucleotide platform
The companies will now begin detailed contract negotiations and proceed with necessary consultations and approval processes
The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities
The savings will be fully reinvested to support new product launches and its pipeline across multiple therapeutic areas
The purpose of this investment is to meet the expenditure relating to the civil works to be undertaken for setting up of a manufacturing facility
Subscribe To Our Newsletter & Stay Updated